Monsurat Gbadamosi, Co-Founder of Droso4Nigeria, Senior Scientist at Vivan Therapeutics, shared a post on LinkedIn:
“Accelerating the Future of Precision Medicine
At Vivan Therapeutics, our focus remains on building scalable, data-driven platforms, TuMatch AI, and the Personal Discovery Process (PDP) to match patient-specific genetic profiles with effective drug combinations. By integrating AI analytics, in vivo validation, and drug repurposing, we’re reducing risk and time in therapeutic development.
As we grow our partnerships and expand our footprint at London’s White City Biotech Hub, we’re creating significant opportunities for collaboration and investment in a rapidly evolving space.
If you’re an investor interested in the intersection of AI, oncology, and real-world biology, we’d love to connect at Vivan Therapeutics.”
More posts featuring Vivan Therapeutics on OncoDaily.